6Buchdunger E, Zimmermann J, Mett H, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative [J]. Cancer Res, 1996, 56(1): 100-104.
7Druker B J, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells [J]. Nat Med, 1996, 2(5): 561-566.
8Deininger MW, Goldman JM, Lydon N, et al. The tyrosine kinase inhibitor CGP 57148B selectively inhibits the growth of BCR-ABL-positive cells [J]. Blood, 1997, 90(9): 3691- 3698.
9Carroll M, Ohno-Jones S, Tamura S, et al. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins [J]. Blood, 1997, 90(12): 4947-4952.
10Gambacorti-Passerini C, le Coutre P, Mologni L, et al. Inhibition of the ABL kinase activity blocks the proliferation ofBCR/ABL+ leukemic cells and induces apoptosis [J]. Blood Cells Mol Dis, 1997, 23(3): 380-394.
6FDA. Label and Approval History[EB/OL]. [2016-03-07] http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index. cfm?fuseaction=Search.Label_ApprovalHistory#1abelinfo.
7Dissolution Methods-Printable List of All Drugs in the Database[EB/OL]. [2016-03-07]. http://www.accessdata.fda. gov/scripts/cder/dissolution/dsp_SearchResults.cfm.
